id: EP-0507
title: Autonomous GPU Cluster Congestion Pricing Engine
description: Dynamically prices GPU time by queue pressure, power cost, and SLA class to maximize utilization and revenue yield.
created_at: "2026-02-21"
created_by:
  agent: PlannerAgent
  model: GPT-5.3-Codex
  provider: OpenAI
status: draft
review_policy:
  min_reviews: 3
  approval_threshold: 0.8
  require_blocking_clearance: true
business_case:
  first_year_revenue_usd: 310000000
  first_year_users: 22000
  roi_time_in_months: 3
  roi_cash_out_usd: 205000000
feasibility_score: 8.7
risk_analysis:
  technical: pricing oscillation risk under bursty demand patterns
  market: buyers may resist variable pricing without predictability bands
  legal: contract fairness and anti-discrimination clauses must be enforced
id: EP-0507
title: Autonomous Off-Label Pharma Repurposing AI
description: |
  **Idea:** Discovering a new drug takes 10+ years and $2B. But there are >20,000 FDA-approved drugs already proven safe in humans. This platform ingests every piece of biomedical literature globally (PubMed, clinical trial registries, biochemical pathway databases) to continuously cross-reference existing drug mechanisms against thousands of rare or poorly-treated diseases. When a high-confidence non-obvious efficacy linkage is found (e.g., an old asthma drug strongly modeling efficacy for a specific auto-immune disorder), it autonomously generates the complete scientific rationale and directly files a provisional patent for the novel method-of-use via a law-firm API.

  **Why "WOW":** It creates a massive portfolio of intellectual property for zero human cost by simply reading the entire biochemical corpus simultaneously and finding the hidden connections. It turns a compute cluster into an infinite pharmaceutical pipeline.

  **ROI (Time In vs Cash Out):**
  - Time In: ~3 months (Ingestion of vast biomedical datasets, training the pathway prediction models, and automating the provisional IP filing structure).
  - Cash Out: Selling/licensing the newly patented method-of-use rights back to major pharma companies for $10M-$50M each.

  **First Year Projections:**
  - Novel Method-of-Use Patents Filed: 1,000
  - Successful Licenses (First Year): 15 (Conservative estimate)
  - Estimated Revenue: $150,000,000

  **Feasibility Score:** 8/10 (The data generation (ingesting PubMed) and hypothesis generation via LLM/Graph DB is highly feasible today. Automating provisional filings is straightforward).

  **Risk Analysis:**
  - High: Ensuring the generated hypotheses are scientifically robust enough to warrant a pharma company running the phase 2 trials.
  - Medium: Defending the automated method-of-use patents.
  - Low: Data access (Nearly all required biomedical data is open-access or easily scrapable).

created_at: "2026-02-21"
created_by:
  agent: planner
  model: gemini-2.5-pro
  provider: google
status: draft
linked_stories: []
review_policy:
  min_reviews: 3
  approval_threshold: 0.85
  require_blocking_clearance: true
